| Document |
Document Title |
|
WO/2017/031038A1 |
The invention relates to salinomycin derivatives such as compounds having the structure of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a therapeutically effective amount of compounds ...
|
|
WO/2017/028927A1 |
The present invention relates to compounds of formula (I) wherein R1, R2, R3, and Z- have one of the meanings as indicated in the specification or a pharmaceutically acceptable salt thereof, to the use of compounds of formula (I) as a me...
|
|
WO/2017/025868A1 |
A compound of Formula (I) is provided: or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula (I) as TD02 inhibitors. The invention also relates to the ...
|
|
WO/2017/025427A1 |
The present invention relates to novel strigolactam derivatives, to processes for preparing these derivatives including intermediate compounds, to plant growth regulator or seed germination promoting compositions comprising these derivat...
|
|
WO/2017/024980A1 |
Disclosed is a crystallization separation method for a nebivolol hydrochloride intermediate mixture, which comprises the following steps: step 1, adding an alcohol solvent or a mixed solvent of an alcohol and an alkane to a nebivolol hyd...
|
|
WO/2017/019589A1 |
The present disclosure features compounds such as those having the Formulae (I) and (II), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The p...
|
|
WO/2017/012970A2 |
Compounds of formula (I) as defined herein, to processes for preparing them, to pesticidal, in particular insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to methods of using them to combat and con...
|
|
WO/2017/014315A1 |
Provided is an EP2 agonist having a high safety. A compound represented by general formula (I) (wherein each symbol is as defined in the description), a salt thereof, an N-oxide derivative thereof, a solvate of the same or a prodrug of t...
|
|
WO/2017/009804A1 |
The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases a...
|
|
WO/2017/005567A1 |
The invention relates to N-(tetrazole-5-yl)- and N-(triazole-5-yl)aryl carboxamide derivatives of the general formula (I) as herbicides. In said formula (I), V, X, and Z represent groups such as hydrogen, and organic groups such as alkyl...
|
|
WO/2017/005069A1 |
The present invention provides a compound which is of formula (II), wherein X is selected from the group consisting of (X) or a pharmaceutically acceptable salt thereof, methods for treating obesity, providing therapeutic weight loss, an...
|
|
WO/2017/006296A1 |
Compounds of Formulas (I) and (II) and salts thereof; methods of making and using the same, including use for inhibiting BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.
|
|
WO/2016/207083A1 |
The invention relates to haloalkylsulphonamide derivatives of the formula (I) wherein A, W, X, m, n, p, R, R1, R2, R5, R6, R7 and R8 are as defined in the specification. Furthermore, the present invention relates to processes for making ...
|
|
WO/2016/210215A1 |
The present invention relates to metallo-beta-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X 2 and R1are as defined herein. The present invention also relates to compositio...
|
|
WO/2016/210054A1 |
The present disclosure encompasses embodiments of a novel near-infrared-emitting molecular fluorophore and probes incorporating said fluorophore advantageous for in vitro and in vivo research studies. The fluorophore is robust, photostab...
|
|
WO/2016/199076A2 |
The present invention relates to crystalline forms of Afatinib and its dimaleate salt. The present invention also relates to processes for the preparation of crystalline forms of Afatinib and its dimaleate salt. The present invention fur...
|
|
WO/2016/197439A1 |
An imidazole ionic liquid-ZnX2/base catalytic system and a method for catalytic preparation of an ethylene carbonate derivative with same. The catalytic system is composed of three ingredients, an imidazole ionic liquid, ZnX2 and a base ...
|
|
WO/2016/201328A1 |
The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy ...
|
|
WO/2016/198144A1 |
The present invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, comprising these compounds. The compounds have a a dibenzofuran, di...
|
|
WO/2016/196593A1 |
Disclosed are compounds of Formula 1, N-oxides of the compounds and salts of the compounds and N-oxides: wherein R1, R2, R3, R4, R5, R6, Q1, Q2, J, YI and Y2 are as defined in the disclosure. Also disclosed are compositions containing th...
|
|
WO/2016/193287A1 |
A compound of Formula (I) wherein the substituents are as defined in claim 1, useful in seed germination promotion.
|
|
WO/2016/196359A1 |
Chemiluminescence imaging probes for in vivo detection of biological molecules, events, or processes. The CLI probes may feature a portion of a fluorescein molecule and a portion of a luminol molecule. The fluorescein molecule and lumino...
|
|
WO/2016/186276A1 |
The present invention relates to an organic compound represented by chemical formula 1, an organic optoelectronic element, and a display device.
|
|
WO/2016/179645A1 |
The present disclosure relates to 4H-pyran compounds of formula (I) and their use in therapy, to compositions and agents comprising said compounds, to methods of treatment using said compounds, and their use in the manufacture of medicam...
|
|
WO/2016/180537A1 |
The present invention relates to substituted quinoxaline derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.
|
|
WO/2016/182840A1 |
The present invention relates to compounds and their use as ligands for mu opioid receptors. Also included are methods for preparing the compounds and pharmaceutical compositions containing the compounds. In one or more embodiments of th...
|
|
WO/2016/178544A2 |
The present invention relates to a novel compound and, more particularly, to a novel compound which forms a deep HOMO, has a high LUMO enabling easy electron blocking, and has an excellent hole mobility, thereby suppressing a roll-off ph...
|
|
WO/2016/179587A1 |
The invention provides compounds that are useful for treating or preventing cancer.
|
|
WO/2016/176560A1 |
The present invention provides unified synthesis of the CI -CI 9 building blocks of halichondrins and analogs theoreof using selective coupling of poly-halogenated nucleophiles in chromium-mediated coupling reactions. The present inventi...
|
|
WO/2016/174334A1 |
The invention relates to a compound having at least one epoxide function which can be synthesised by an epoxidation reaction of a compound having at least one hydroxyl function obtained by depolymerisation of condensed tannins by a nucle...
|
|
WO/2016/169858A1 |
The invention relates to compounds of formula (I) wherein R1 represents an organic group having a (meth)acrylic group, and R2, R3 and R4 independently of one another represent an H atom or a C1 to C10 alkyl group.
|
|
WO/2016/162870A1 |
Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis is described. Va...
|
|
WO/2016/162405A1 |
The present invention relates to compounds and compositions for use in methods of treating and/or preventing conditions, disorders or diseases that are mediated or caused by a virus.
|
|
WO/2016/161279A1 |
There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, suc...
|
|
WO/2016/156282A1 |
The present invention relates to a novel triazole compound and its salts and N-oxides, a composition comprising such compound, a method for curatively or preventively controlling phytopathogenic harmful fungi of plants or crops comprisin...
|
|
WO/2016/151009A1 |
The invention relates to compounds having general formula (I): where R = H, CH2-OH, CH2-O-CO-CH3, CH2-O-CO-Ph (Ph=phenyl) R' = H, CH2-O-CO-CH3, CH2-O-CO-Ph (Ph = phenyl) Ar = phenyl, 3-methoxy-4-hydroxy phenyl, 2-furyl. These are compoun...
|
|
WO/2016/148150A1 |
A tetracarboxylic dianhydride represented by formula (1), and a polyimide or polyimide copolymer produced from this tetracarboxylic dianhydride, are used. This makes it possible to provide a polyimide and a polyimide copolymer having exc...
|
|
WO/2016/148390A1 |
The present disclosure relates to a plurality of host materials and organic electroluminescent device comprising the same. By comprising a specific combination of a plurality of host materials, the organic electroluminescent device of th...
|
|
WO/2016/149271A1 |
Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pa...
|
|
WO/2016/144351A1 |
Disclosed are compounds of Formula (I), including all geometric and stereoisomers, N-oxides, and salts thereof, Formula (I) wherein Q is Formula (I) and A, R1, m, X1, X2, X3, X4, Y1, Y2 and Y3 are as defined in the disclosure. Also discl...
|
|
WO/2016/144678A1 |
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein Q is Q-1, Q-2, Q-3 or Q-4 and A, R1, m, X1, X2, X3, X4, Y1, Y2 and Y3 are as defined in the disclosure. Also disclosed ...
|
|
WO/2016/143634A1 |
Provided is a bimesogenic compound which exhibits high solubility in other bimesogenic compounds and substances used in conventional liquid crystal display elements, such as liquid crystalline compounds, liquid crystal compositions, chir...
|
|
WO/2016/142797A1 |
Derivatives of verbascoside and the pharmaceutical compositions containing them are the subject matter of the present invention. In particular, the present invention relates to compounds of Formula (I), wherein R, R1, R2 and R3 are the s...
|
|
WO/2016/140459A1 |
The present invention provides: a novel structure of a phosphorus-based epoxy compound having a high phosphorus (P) content and having high heat resistance and low dielectric characteristics; a method for preparing a phosphorus-based epo...
|
|
WO/2016/131098A1 |
ABSTRACT The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in ...
|
|
WO/2016/131431A1 |
The invention relates to novel solid forms of empagliflozin of formula I, with the systematic name (2S,3R54R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphen
yl]methyl]phenyl]-6- (hydroxy-methyl)oxane-3,4,5-triol. It deals with an amor...
|
|
WO/2016/123426A2 |
Various esterified alkyl ketal ester or hydroxyalkyl ketal ester products are useful as components of organic polymer compositions. The ketal esters are produced in certain transesterifications between alkyl ketal esters and/or hydroxyal...
|
|
WO/2016/118774A1 |
The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfuncti...
|
|
WO/2016/111347A1 |
Provided is a drug the active ingredient of which is a compound having antagonistic activity against EP4 receptor in the prevention and/or treatment of disease attributed to activation of EP4 receptor. The compound represented by general...
|
|
WO/2016/110250A1 |
Provided in the present invention are a mangiferin-6-O-berberine salt and a preparation method thereof. In addition, also provided is a use of the mangiferin-6-O-berberine salt as an AMPK activator for treating diabetes, etc.
|
